ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the
safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in
combination with bevacizumab in subjects with recurrent mCRC.